Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India
Bristol Myers Squibb (BMS) announced the launch of Kopozgo (Mavacamten) in India. Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (oHCM).
Kopozgo is the first in-class disease-specific treatment targeting the core pathophysiological mechanism 3 of obstructive HCM, leading to improvement in the functional capacity of the heart and symptoms.
Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO) with an import license issued on March 6, 2025. Kopozgo is now available to patients in India. The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM.
Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, “With the launch of Kopozgo in India, patients with oHCM now have a promising first-in-class treatment option. This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care for patients in India.”
